Enzychem Lifesciences Balance Sheet Health
Financial Health criteria checks 6/6
Enzychem Lifesciences has a total shareholder equity of ₩178.7B and total debt of ₩3.7B, which brings its debt-to-equity ratio to 2%. Its total assets and total liabilities are ₩189.3B and ₩10.6B respectively.
Key information
2.0%
Debt to equity ratio
₩3.66b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩116.29b |
| Equity | ₩178.68b |
| Total liabilities | ₩10.64b |
| Total assets | ₩189.32b |
Recent financial health updates
Enzychem Lifesciences (KOSDAQ:183490) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 13
Rock star Growth Puts Enzychem Lifesciences (KOSDAQ:183490) In A Position To Use Debt
May 09Recent updates
Enzychem Lifesciences (KOSDAQ:183490) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 13There's Reason For Concern Over Enzychem Lifesciences Corporation's (KOSDAQ:183490) Price
Aug 13Rock star Growth Puts Enzychem Lifesciences (KOSDAQ:183490) In A Position To Use Debt
May 09If You Had Bought Enzychem Lifesciences (KOSDAQ:183490) Shares A Year Ago You'd Have Earned 43% Returns
Feb 17
Financial Position Analysis
Short Term Liabilities: A183490's short term assets (₩156.1B) exceed its short term liabilities (₩8.8B).
Long Term Liabilities: A183490's short term assets (₩156.1B) exceed its long term liabilities (₩1.9B).
Debt to Equity History and Analysis
Debt Level: A183490 has more cash than its total debt.
Reducing Debt: A183490's debt to equity ratio has reduced from 4% to 2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A183490 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A183490 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 3% each year